BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27512631)

  • 1. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    Springerplus; 2016; 5(1):1172. PubMed ID: 27512631
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Chang XY; Wu Y; Jiang Y; Wang PY; Chen J
    Gastroenterol Res Pract; 2020; 2020():1457452. PubMed ID: 32934653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
    Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
    J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
    Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
    Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.
    Amato E; Molin MD; Mafficini A; Yu J; Malleo G; Rusev B; Fassan M; Antonello D; Sadakari Y; Castelli P; Zamboni G; Maitra A; Salvia R; Hruban RH; Bassi C; Capelli P; Lawlor RT; Goggins M; Scarpa A
    J Pathol; 2014 Jul; 233(3):217-27. PubMed ID: 24604757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.
    Singhi AD; Nikiforova MN; Fasanella KE; McGrath KM; Pai RK; Ohori NP; Bartholow TL; Brand RE; Chennat JS; Lu X; Papachristou GI; Slivka A; Zeh HJ; Zureikat AH; Lee KK; Tsung A; Mantha GS; Khalid A
    Clin Cancer Res; 2014 Aug; 20(16):4381-9. PubMed ID: 24938521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNF43 mutation frequently occurs with GNAS mutation and mucin hypersecretion in intraductal papillary neoplasms of the bile duct.
    Tsai JH; Liau JY; Yuan CT; Cheng ML; Yuan RH; Jeng YM
    Histopathology; 2017 Apr; 70(5):756-765. PubMed ID: 27864998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of GNAS and KRAS mutations in pancreatic cysts.
    Lee LS; Doyle LA; Houghton J; Sah S; Bellizzi AM; Szafranska-Schwarzbach AE; Conner JR; Kadiyala V; Suleiman SL; Banks PA; Andruss BF; Conwell DL
    JOP; 2014 Nov; 15(6):581-6. PubMed ID: 25435574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
    Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
    Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms.
    Huang B; Trujillo MA; Fujikura K; Qiu M; Chen F; Felsenstein M; Zhou C; Skaro M; Gauthier C; Macgregor-Das A; Hutchings D; Hong SM; Hruban RH; Eshleman JR; Thompson ED; Klein AP; Goggins M; Wood LD; Roberts NJ
    J Pathol; 2020 Nov; 252(3):252-262. PubMed ID: 32696980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How does intestinal-type intraductal papillary mucinous neoplasm emerge? CDX2 plays a critical role in the process of intestinal differentiation and progression.
    Omori Y; Ono Y; Kobayashi T; Motoi F; Karasaki H; Mizukami Y; Makino N; Ueno Y; Unno M; Furukawa T
    Virchows Arch; 2020 Jul; 477(1):21-31. PubMed ID: 32291497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
    Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of EUS-acquired pancreatic cyst fluid for KRAS and GNAS mutations for diagnosis of intraductal papillary mucinous neoplasia and mucinous cystic lesions: a systematic review and meta-analysis.
    McCarty TR; Paleti S; Rustagi T
    Gastrointest Endosc; 2021 May; 93(5):1019-1033.e5. PubMed ID: 33359054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas.
    Furukawa T; Kuboki Y; Tanji E; Yoshida S; Hatori T; Yamamoto M; Shibata N; Shimizu K; Kamatani N; Shiratori K
    Sci Rep; 2011; 1():161. PubMed ID: 22355676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis.
    Tamura K; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Ideno N; Aso T; Miyazaki T; Ohuchida K; Takahata S; Ito T; Ushijima Y; Oda Y; Mizumoto K; Tanaka M
    Surgery; 2015 Feb; 157(2):277-84. PubMed ID: 25530484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activating mutations of GNAS and KRAS in cystic fluid can help detect intraductal papillary mucinous neoplasms of the pancreas.
    Frampton AE; Stebbing J; Gall TM; Silver B; Jiao LR; Krell J
    Expert Rev Mol Diagn; 2015 Mar; 15(3):325-8. PubMed ID: 25656048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct.
    Yang CY; Huang WJ; Tsai JH; Cheng A; Chen CC; Hsu HP; Jeng YM
    Mod Pathol; 2019 Nov; 32(11):1637-1645. PubMed ID: 31231124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm.
    Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T
    Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.